The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2093 - 2104
Edoxaban, an oral factor Xa inhibitor, was noninferior to warfarin in the prevention of stroke or systemic embolism in patients with atrial fibrillation. There...
STROKE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | PHARMACOKINETICS | SAFETY | ORAL ANTICOAGULANTS | PREVENTION | GENERATION | FACTOR XA INHIBITOR | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Follow-Up Studies | Atrial Fibrillation - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Warfarin - adverse effects | Anticoagulants - therapeutic use | Male | Thiazoles - therapeutic use | Anticoagulants - adverse effects | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Adult | Female | Aged | Hemorrhage - chemically induced | Pyridines - therapeutic use | Warfarin | Anticoagulants (Medicine) | Research | Comparative analysis | Drug therapy | Atrial fibrillation | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Risk groups | Glycoproteins | Patients | Bleeding | Embolism | Manuscripts | Fibrillation | Motivation | Death | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Cardiovascular Diseases | Enoxaparin | Hemorrhage | Life Sciences | Atrial Fibrillation
STROKE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | PHARMACOKINETICS | SAFETY | ORAL ANTICOAGULANTS | PREVENTION | GENERATION | FACTOR XA INHIBITOR | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Follow-Up Studies | Atrial Fibrillation - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Warfarin - adverse effects | Anticoagulants - therapeutic use | Male | Thiazoles - therapeutic use | Anticoagulants - adverse effects | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Adult | Female | Aged | Hemorrhage - chemically induced | Pyridines - therapeutic use | Warfarin | Anticoagulants (Medicine) | Research | Comparative analysis | Drug therapy | Atrial fibrillation | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Risk groups | Glycoproteins | Patients | Bleeding | Embolism | Manuscripts | Fibrillation | Motivation | Death | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Cardiovascular Diseases | Enoxaparin | Hemorrhage | Life Sciences | Atrial Fibrillation
Journal Article
IEEE Transactions on Geoscience and Remote Sensing, ISSN 0196-2892, 06/2007, Volume 45, Issue 6, pp. 1671 - 1680
Landslides triggered by rainfall can possibly be foreseen in real time by jointly using rainfall intensity-duration thresholds and information related to land...
Real time systems | Land surface | natural disasters | Terrain factors | Hazards | Surface topography | real-time precipitation analysis | Remote sensing | satellite remote sensing | Condition monitoring | Satellites | landslide susceptibility (LS) | Landslide | Surface texture | Remote monitoring | Satellite remote sensing | Landslide susceptibility (LS) | Real-time precipitation analysis | Natural disasters | DEBRIS FLOWS | PUERTO-RICO | HAZARD ZONATION | SUSCEPTIBILITY | INTENSITY | landslide | HONG-KONG | ENGINEERING, ELECTRICAL & ELECTRONIC | GIS | GEOCHEMISTRY & GEOPHYSICS | REMOTE SENSING | PRECIPITATION | MODELS | LANTAU ISLAND | Landslides | Technology application | Usage | Emergency management | Geospatial imaging | Forecasts and trends | Satellite imaging | Studies | Models | Landslides & mudslides | Availability | Rainfall | Real time | Texture
Real time systems | Land surface | natural disasters | Terrain factors | Hazards | Surface topography | real-time precipitation analysis | Remote sensing | satellite remote sensing | Condition monitoring | Satellites | landslide susceptibility (LS) | Landslide | Surface texture | Remote monitoring | Satellite remote sensing | Landslide susceptibility (LS) | Real-time precipitation analysis | Natural disasters | DEBRIS FLOWS | PUERTO-RICO | HAZARD ZONATION | SUSCEPTIBILITY | INTENSITY | landslide | HONG-KONG | ENGINEERING, ELECTRICAL & ELECTRONIC | GIS | GEOCHEMISTRY & GEOPHYSICS | REMOTE SENSING | PRECIPITATION | MODELS | LANTAU ISLAND | Landslides | Technology application | Usage | Emergency management | Geospatial imaging | Forecasts and trends | Satellite imaging | Studies | Models | Landslides & mudslides | Availability | Rainfall | Real time | Texture
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article